Stratatech Successfully Completes Clinical Trial Of StrataGraft^ Skin Substitute - Trial's Primary Clinical Endpoint Achieved

Stratatech Corp. , a regenerative medicine company focused on the development and commercialization of cell-based, tissue-engineered skin substitute products, today announced that it has successfully completed the multi-center, 15-patient clinical trial of its StrataGraft^